RHYTHM PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

RYTM$113.95+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)


· · · · · · · · · · Accumulated · · · · ·
· · · · · · · Additional · · Other · · · · · Total
· · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’
· Shares · Amount · Capital · Income (Loss) · · Deficit · Equity
Balance at December 31, 2020	44,235,903	44	625,762	49	(459,327)	166,528
Stock compensation expense	—	—	20,804	—	—	20,804
Issuance of common stock in connection with ESPP	38,051	—	621	—	—	621
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units	259,620	—	4,134	—	—	4,134
Issuance of common stock upon completion of public offering, net of offering costs	5,750,000	6	161,720	—	—	161,726
Net unrealized loss on marketable securities	—	—	—	(50)	—	(50)
Net loss	—	—	—	—	(69,612)	(69,612)
Balance at December 31, 2021	50,283,574	$50	$813,041	$(1)	$(528,939)	$284,151
Stock compensation expense	—	—	19,831	—	—	19,831
Issuance of common stock in connection with ESPP	92,932		626	—	—	626
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units	855,923	1	9,751	—	—	9,752
Issuance of common stock upon completion of public offering, net of offering costs	5,380,000	5	131,107	—	—	131,112
Net unrealized loss on marketable securities	—	—	—	(91)	—	(91)
Net loss	—	—	—	—	(181,119)	(181,119)
Balance at December 31, 2022	56,612,429	$56	$974,356	$(92)	$(710,058)	$264,262
Stock compensation expense	—	—	32,553	—	—	32,553
Issuance of common stock in connection with ESPP	49,819	—	1,053	—	—	1,053
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units	745,066	1	7,467	—	—	7,468
Issuance of common stock upon completion of ATM equity offering, net of offering costs	2,019,245	2	48,873	—	—	48,875
Foreign currency translation adjustment				(140)		(140)
Net unrealized gain on marketable securities	—	—	—	366	—	366
Net loss	—	—	—	—	(184,678)	(184,678)
Balance at December 31, 2023	59,426,559	$59	$1,064,302	$134	$(894,736)	$169,759

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.